MP34-10 CHARACTERISING PROSTATE DUCTAL ADENOCARCINOMA: MORPHOMETRY AND CLINICAL OUTCOMES

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History II1 Apr 2018MP34-10 CHARACTERISING PROSTATE DUCTAL ADENOCARCINOMA: MORPHOMETRY AND CLINICAL OUTCOMES Timothy Harkin, Ashish Chandra, Oussama Elhage, Mark Frydenberg, and Prokar Dasgupta Timothy HarkinTimothy Harkin More articles by this author , Ashish ChandraAshish Chandra More articles by this author , Oussama ElhageOussama Elhage More articles by this author , Mark FrydenbergMark Frydenberg More articles by this author , and Prokar DasguptaProkar Dasgupta More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1102AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Ductal adenocarcinoma is a rare variant of prostate cancer, demonstrating a more aggressive phenotype than conventional acinar adenocarcinoma. Morphometric variables, including distance from the urethra and tumour volume, remain unclear in present literature.This study aimed to examine the relationship between morphometry and clinical outcomes, particularly biochemical recurrence, and to further characterise the morphometry of ductal tumours. METHODS A comparative cohort study of ductal and Gleason 8+ acinar adenocarcinoma patients who had undergone radical prostatectomy between February 2007 and February 2017 was undertaken. Ductal and acinar foci were outlined under direct microscopy and morphometric measurements taken. MRI and clinical data were then compared. RESULTS 68 ductal and 72 acinar adenocarcinomas were included. Ductal tumours were located further from the periphery by 0.3 mm (p = 0.02), and involved 5% more prostate area (p = 0.02). Ductal proportions were reported in 52.7% of cases and identified in another 5% initially labelled as acinar-only. Risk of biochemical recurrence increased per 10% ductal components (HR 1.129, 95%CI 1.023–1.246, p = 0.02), and was substantially higher in tumours with ductal components greater than 50% (HR 2.226, 95%CI 1.110–4.464, p = 0.024). CONCLUSIONS This is the first study to demonstrate a significant relationship between the proportion of ductal components and clinical outcomes, and our findings suggest that more aggressive management strategies are required for patients with higher ductal proportions. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e441 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Timothy Harkin More articles by this author Ashish Chandra More articles by this author Oussama Elhage More articles by this author Mark Frydenberg More articles by this author Prokar Dasgupta More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...